Impact of the COVID-19 outbreak on the field of hematopoietic cell transplantation in the Asia-Pacific region: APBMT Activity Survey 2020/2021.

COVID-19 became a global pandemic in 2020 and significantly affected the activity of hematopoietic cell transplants (HCT) worldwide. Despite these challenges, a total of 28,793 transplants, including 18,518 allogeneic and 10,275 autologous transplants, were performed in 719 facilities in 2020 in the Asia-Pacific (AP) region. This represented a 5.

Dietary intake, energy availability, and power in men collegiate gymnasts.

Introduction: The purpose was to examine the prevalence of low energy availability (LEA), explore dietary behaviors in men collegiate gymnasts ( = 14), and investigate the relationships between energy availability (EA), body composition, and plyometric performance.

Methods: Body composition was measured using air displacement plethysmography. Lower- and upper-body peak power (PWRpeak) and modified reactive strength index (RSI) were calculated from countermovement jump (CMJ) and plyometric push-up (PP) assessments.

Safe Hypofractionation Amid Diverse Technologies: Using Teamwork to Manage the Complexity.

Radiation oncology caregivers worldwide are dedicated to advancing cancer treatment with the ultimate goal of eradicating the disease. Recognizing the inherent complexity of cancer treatment using hypo-fractionation radiotherapy (HFRT), these caregivers are committed to exploring avenues for progress and providing personalized care to each patient. Strong teams and effective workflows are an essential component to implementing safe HFRT.

Suppressed thyroid stimulating hormone levels after initiation of a subcutaneous glucagon-like peptide-1 receptor agonist in a post-thyroidectomy patient managed with levothyroxine case report.

Objectives: Glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy has demonstrated an increased risk of thyroid C-cell hyperplasia and C-cell tumors in rodents. Due to this risk, a boxed warning for this drug class exists for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. There is a lack of data regarding any possible effect of GLP-1 RA therapy on serum thyroid levels.